Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study - 21/08/11
, Thomas Werfel, MD b, Regina Fölster-Holst, MD c, Jean-Paul Ortonne, MD d, Paul C. Potter, MD e, Yves de Prost, MD f, Miles J. Davidson, MD g, Nathalie Barbier, MSc h, Hans-Peter Goertz, MPH h, Carle Paul, MD h
Reprint requests: Kim A. Papp, MD, PhD, FRCP, Probity Medical Research, 135 Union Street East, Waterloo, Ontario N2J 1C4, Canada.Waterloo, Canada; Hannover and Kiel, Germany; Nice and Paris, France; Cape Town, South Africa; Dronfield, United Kingdom; and Basel, Switzerland
Résumé |
Objective and methods |
The safety and efficacy of treatment with pimecrolimus cream 1% was evaluated for up to 2 years in infants and young children with atopic dermatitis. Ninety-one patients participated in a 1-year, open-label extension to a 1-year double-blind study. Of these, 76 received pimecrolimus for 2 years. Pimecrolimus was applied twice daily at the first signs or symptoms of the disease until clearance. Outcome measures included the incidence of adverse events and the Eczema Area and Severity Index (EASI).
Results |
No patient discontinued because of adverse events. The incidence of systemic and skin infections did not increase over time. Over the 2-year period, 2 patients experienced an episode of clinically diagnosed eczema herpeticum. In patients receiving pimecrolimus for 2 years, the mean decrease in EASI score from baseline was 68.7% at 3 months and 70.8% at 24 months.
Conclusion |
Treatment with pimecrolimus cream 1% for up to 2 years was well tolerated and resulted in a marked and sustained improvement of atopic dermatitis.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AD, EASI, IGA, NOS, NEC, SEM, TBSA, UVA/B
Plan
| Sponsored by Novartis Pharma. Ms N. Barbier, Mr H.-P. Goertz, and Dr C. Paul hold permanent positions with Novartis Pharma. The other authors have no potential conflicts of interest or competing interests to disclose. This study was presented in abstract form at the meeting of the European Academy of Dermatology and Venereology, October 2003. |
Vol 52 - N° 2
P. 240-246 - février 2005 Retour au numéro
Article précédent
- Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy
- Cheryl M. Burgess, Rafaela M. Quiroga
- Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination
- Kim A. Papp, Kristine Breuer, Michael Meurer, Jean-Paul Ortonne, Paul C. Potter, Yves de Prost, Miles J. Davidson, Nathalie Barbier, Hans-Peter Goertz, Carle Paul
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?